胃癌术后Xelox方案同期联合适形调强放疗的临床观察(1)
 |
| 第1页 |
参见附件。
【摘要】目的:评价胃癌患者术后CapeOX方案同期联合调强放疗的近期疗效和毒性反应。方法：从2007年9月至2010年9月，41例胃癌术后患者采用化疗采用Xelox方案，卡培他滨1250 mg/m2 ，口服(2次/d)，1-14d；奥沙利铂130 mg/m2，持续静脉滴注2～3 h，1 d。同步适形调强放疗，靶区包括瘤床和区域淋巴引流区。放化疗后辅助化疗以Xelox方案4～6疗程，观察近期疗效及毒性反应。结果：全组1 年总生存率、无复发生存率和局部区域控制率分别为90.2% 、80.5%和95.1% 。有3例中断同步放化疗。Ⅲ度骨髓抑制4例，Ⅲ度胃肠道反应5例。结论：胃癌患者术后CapeOX方案同期联合调强放疗的近期疗效较好，毒性反应是可耐受的。
【关键词】胃癌;放疗;卡培他滨;奥沙利铂;副作用
The Observation of Short Term Result of Xelox Plus Concurrent Conformal
Intensity Modulated Radiation Therapy for Postoperation Patients With Gastric Cancer
DU Xaio-bo,PU Jing, Zhao Zhen-hua, et al
【Abstract】 Objective;To evaluate the short-term efficacy and toxicity of Xelox plus concurrent conformal intensity modulated radiation therapy for postoperation patients with gastric cancer. Methods: Form September 2007 to September 2010, 41 postoperation gastric cancer patients were treated with Xelox plus concurrent conformal intensity modulated radiation therapy. The Xelox regimen was capecitabine 1250 mg/m2, orally bid, day1to 14, oxaliplatin 130 mg/m2, continuous infusion 2 to 3h, day1. Intensity modulated radiation therapy: target volume including the tumor bed and regional lymphatic drainage area, the radiation dose is 45GY/25 fractions. After chemoradiotherapy, those patients were treatedwith4 to 6 cycles Xelox regimen. Efficacy and toxicity will be observed. Results: The 1-year overall survival, relapse-free survival and locoregional control rates of 41 patients were 90.2%, 80.5% and 95.1%. 3 patients interrupted chemoradiotherapy. Ⅲ myelosuppression occurred in 4 cases and Ⅲ degree of gastrointestinal toxicity occurred in in 5 cases. Conclusion: The short-term efficacy of Xelox plus concurrent conformal intensity modulated radiation therapy for postoperation patients with gastric cancer was good, and toxicity was tolerable.
【Keywords】 Gastric Cancer, Radiotherapy, Capecitabine, Oxaliplatin, Side Effects
【中图分类号】R136.01 【文献标识码】B【文章编号】1005-0515(2011)08-0394-02
前言：
胃癌在全球的发病率排在所有肿瘤的第4位，胃癌是我国最常见的恶性肿瘤之一.中国胃癌男女人口调整死亡率(男性：40.8/10万，女性：18.6/10万，男性是女性的1.9倍)分别是欧美发达国家的4.2-7.9倍和3.8-8.0倍。上海胃癌粗死亡率男性为52.24/10万，居恶性肿瘤发病第二位，女性为29.26/10万，居恶性肿瘤的第三位[1]。多数胃癌患者就诊时已处于进展期，早期胃癌比例不足l0%，因为诊断时晚期胃癌较多 ......
您现在查看是摘要介绍页，详见PDF附件(2841kb)。